Sukharomana M.Udomittipong K.Ruangchira-Urai R.Charuvanij S.Mahidol University2023-06-182023-06-182022-06-01Asian Pacific Journal of Allergy and Immunology Vol.40 No.2 (2022) , 173-1770125877Xhttps://repository.li.mahidol.ac.th/handle/20.500.14594/84981Background: Nonspecific interstitial pneumonia (NSIP) is a rare pulmonary complication in systemic juvenile idiopathic arthritis (SJIA). Objective: To present a case with NSIP in SJIA Methods: Case report Results: We report the case of a 4-year-old boy with SJIA complicated by macrophage activation syndrome (MAS) refractory to conventional therapy, and who later developed NSIP confirmed by high-resolution computerized tomography of the chest and lung histopathology. The patient received tocilizumab, a monoclonal antibody to interleukin-6 receptor, to control his disease. Data relating to tocilizumab treatment of NSIP in refractory SJIA is limited. Conclusions: The data from this case report suggests that NSIP could be a pulmonary complication of SJIA complicated by MAS that is refractory to conventional therapy. Early initiation of tocilizumab should be considered to achieve disease remission in this pediatric patient population.Immunology and MicrobiologyArticleSCOPUS10.12932/ap-050819-06162-s2.0-851306340782228869431837211